Evidence map›Paper›PMID 36910081›Full record

ArticleJournal of thoracic disease2023

MicroRNA-186-5p inhibits H9c2 cells apoptosis induced by oxygen-glucose deprivation by targeting ERK1/2.

Wennan Nie, Jia Wu, Xiaoyang Yu, Zhuolin Li, Xiaomin Cai, Wenyan Wei, Cheng Wang, Junjun Wang

Abstract read
In one paragraph

Article in Journal of thoracic disease, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Wennan Nie *Department of Clinical Laboratory, Jinling Hospital, Medical School of Nanjing University, Nanjing, China.
Jia Wu *Department of Clinical Laboratory, Jinling Hospital, Medical School of Nanjing University, Nanjing, China.
Xiaoyang Yu *Department of Clinical Laboratory, Jinling Hospital, Medical School of Nanjing University, Nanjing, China.
Zhuolin LiDepartment of Clinical Laboratory, Jinling Hospital, Medical School of Nanjing University, Nanjing, China.
Xiaomin CaiDepartment of Cardiology, Jinling Hospital, Medical School of Nanjing University, Nanjing, China.
Wenyan WeiDepartment of Clinical Laboratory, Jinling Hospital, Medical School of Nanjing University, Nanjing, China.
Cheng WangDepartment of Clinical Laboratory, Jinling Hospital, Medical School of Nanjing University, Nanjing, China.
Junjun WangDepartment of Clinical Laboratory, Jinling Hospital, Medical School of Nanjing University, Nanjing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Serum miR-186-5p levels are increased in acute myocardial infarction (AMI) patients and might contribute to assessing the prognosis of AMI patients. In this study, we further investigated the underlying molecular mechanism of miR-186-5p that participated in the pathological processes of myocardial ischemia. Methods: The AMI models of rats and oxygen-glucose deprivation (OGD) models of H9c2 cells were established. Bioinformatics databases, luciferase reporting, and western blotting assays were performed to identify the regulatory target of miR-186-5p. Transfection and functional experiments were conducted to further define the possible molecular mechanism of miR-186-5p during the process of glucose deficiency and hypoxia. Results: The level of miR-186-5p was found to significantly decrease in H9c2 cells after OGD treatment, while it increased in the culture medium from OGD-treated H9c2 cells. Using bioinformatics databases, luciferase reporting, and western blotting assays, we identified that ERK1/2 might serve as the negative regulatory target of miR-186-5p. Combined with further transfection experiments, we indicated that miR-186-5p might inhibit the expression and activation of ERK1/2. This finding was also reflected in the reduction of their downstream cleaved caspase-3. Through functional experiments, we revealed that miR-186-5p might inhibit apoptosis and promote proliferation in OGD-treated H9c2 cells. Conclusions: We demonstrated that miR-186-5p might suppress OGD-induced apoptosis in H9c2 cells by targeting the ERK1/2 pathway.

Indexed as

apoptosisERK1/2H9c2miR-186-5poxygen-glucose deprivation

Identifiers

PMID36910081
PMCPMC9992618

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.